Mirae Asset Global Investments Co. Ltd. Raises Stock Position in Repligen Co. (NASDAQ:RGEN)

Mirae Asset Global Investments Co. Ltd. raised its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 46.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 18,629 shares of the biotechnology company's stock after purchasing an additional 5,913 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in Repligen were worth $2,679,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the company. GAMMA Investing LLC grew its position in Repligen by 24.0% during the third quarter. GAMMA Investing LLC now owns 594 shares of the biotechnology company's stock worth $88,000 after buying an additional 115 shares in the last quarter. CWM LLC boosted its position in shares of Repligen by 36.3% during the 3rd quarter. CWM LLC now owns 428 shares of the biotechnology company's stock valued at $64,000 after acquiring an additional 114 shares during the last quarter. UMB Bank n.a. grew its holdings in shares of Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Creative Planning increased its position in shares of Repligen by 32.6% in the third quarter. Creative Planning now owns 5,123 shares of the biotechnology company's stock worth $762,000 after purchasing an additional 1,259 shares during the last quarter. Finally, NBC Securities Inc. raised its stake in Repligen by 92.2% in the third quarter. NBC Securities Inc. now owns 2,931 shares of the biotechnology company's stock valued at $436,000 after purchasing an additional 1,406 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

RGEN has been the subject of a number of research reports. Canaccord Genuity Group started coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target for the company. Wolfe Research assumed coverage on Repligen in a research note on Thursday, November 14th. They issued a "peer perform" rating on the stock. StockNews.com upgraded Repligen from a "sell" rating to a "hold" rating in a research report on Friday, January 3rd. Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price objective for the company. Finally, TD Cowen started coverage on Repligen in a report on Monday. They set a "buy" rating and a $200.00 price objective on the stock. Six analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $186.00.

Repligen Trading Up 0.3 %

Shares of Repligen stock traded up $0.45 on Thursday, hitting $146.17. The stock had a trading volume of 519,443 shares, compared to its average volume of 552,770. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a one year low of $113.50 and a one year high of $211.13. The stock's 50-day simple moving average is $155.39 and its two-hundred day simple moving average is $149.11. The stock has a market cap of $8.19 billion, a price-to-earnings ratio of -395.04, a PEG ratio of 4.54 and a beta of 0.99.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, beating the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company's quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.23 earnings per share. As a group, sell-side analysts predict that Repligen Co. will post 1.54 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.